Modernizing Neuroscience Clinical Trials Using a Virtual Framework: A Perspective on Endpoint Measurement and Best Practices

Tetyana Korchak, MD, Executive Director, Neuroscience, Ophthalmology and Women’s Health, Clinical Development Solutions, Labcorp Drug Development

Dr. Tetyana Korchak has medical training in ophthalmology, with over 20 years of industry experience at CRO, biotech and investigative site settings across a broad range of therapeutic areas, including but not limited to neuroscience, oncology, ophthalmology and women’s health.

Specific to neuroscience, her expertise encompasses neurodegenerative, acute and rare neurology and various psychiatric diseases. She also has deep experience supporting translational/early phase development through product launch, late-phase/post-marketing studies, encompassing clinical development strategy and planning, program feasibility, risk assessment and execution.

Vanessa Patel, MS, PhD, Director, Patient-Centered Assessment, Labcorp Drug Development

Vanessa Perez Patel, MS, PhD is a formally trained epidemiologist and biostatistician with over 10 years of experience in scientific consulting and the pharmaceutical industry where she has led and implemented global health economic and outcomes research strategies in support of various indications across portfolios largely spanning neuroscience, infectious disease, women’s health and rare disease.

Her expertise in neuroscience encompasses the demonstration of multi-stakeholder value of therapies in development for psychiatric illness and neuro-genetic disorders including conditions associated with cognitive and behavioral issues. She holds advanced degrees in Epidemiology and Biostatistics from the University of Michigan, Ann Arbor, and a degree in Applied Mathematics from the University of California, Los Angeles.

Elan Cohen, PhD, Principal Investigator, Hassman Research Institute

Dr. Elan Cohen is currently a Principal Investigator at Hassman Research Institute (HRI) located in Marlton, NJ where inpatient and outpatient Phase I-IV Healthy Normals, CNS and medically focused clinical trials are conducted. Stemming from his work at HRI as well as his previous role as Director at a rater training vendor and CRO, since 2007 in the clinical trial industry, Dr. Cohen’s experience and expertise has extended to developing and writing clinical trial protocols, rater training, data surveillance, psychiatric scale management and applying such evaluations into clinical trial methodologies, integrating regulatory compliance matters with rater training programs and implementing systemic strategies aimed to reduce the placebo and nocebo effects. Dr. Cohen has presented at Investigators’ Meetings and industry conferences and has been published regarding empirical explorations of placebo and nocebo effect mitigations, namely Dr. Hassman and his proprietary Placebo-Control Reminder Script (PCRS). Dr. Cohen is also a Licensed Psychologist in Pennsylvania and New Jersey.